GLP-1 for Type 2 Diabetes

Type 2 diabetes (T2D) is a chronic metabolic disorder in which cells become resistant to insulin and the pancreas cannot produce enough insulin to maintain normal blood glucose. It affects an estimated 37 million Americans and is a leading driver of cardiovascular disease, chronic kidney disease, and vision loss in adults.

GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide are now recommended as high-priority pharmacotherapy for T2D, particularly in people who also have cardiovascular disease, heart failure, or obesity. Both Ozempic (semaglutide) and Mounjaro (tirzepatide) carry FDA approval specifically for glycemic control in adults with type 2 diabetes.

These medications lower blood sugar through multiple mechanisms — stimulating glucose-dependent insulin release, suppressing glucagon, slowing gastric emptying, and reducing appetite — producing meaningful A1c reductions alongside substantial weight loss. Unlike older diabetes drugs, they do not cause hypoglycemia when used without insulin or sulfonylureas.

The SUSTAIN-1 trial established semaglutide 0.5 mg and 1.0 mg as effective monotherapy for drug-naive T2D, reducing A1c by 1.45% and 1.55% respectively versus a 0.02% increase on placebo over 30 weeks [4].

Head-to-head, tirzepatide outperformed semaglutide in the SURPASS-2 trial. Tirzepatide 10 mg and 15 mg reduced A1c by 2.24% and 2.30% compared with 1.86% for semaglutide 1 mg, and produced significantly greater weight loss (9.3 kg and 11.2 kg vs 5.7 kg) [2].

SURPASS-1 showed tirzepatide 5/10/15 mg reduced A1c by 1.87%/1.89%/2.07% versus placebo in T2D patients on diet and exercise alone, demonstrating potent glucose lowering as monotherapy [5].

The SUSTAIN-8 trial showed semaglutide superior to canagliflozin as an add-on to metformin, cutting A1c by 1.5% versus 1.0% and body weight by 5.3 kg versus 4.2 kg [7].

In people with T2D and obesity, semaglutide 2.4 mg (STEP 2) reduced body weight by 9.6% versus 3.4% with placebo over 68 weeks — meaningful in T2D because sustained weight loss directly improves insulin sensitivity [6].

The cardiovascular outcomes are equally important. SUSTAIN-6 demonstrated that semaglutide reduced 3-point MACE (cardiovascular death, nonfatal MI, nonfatal stroke) by 26% versus placebo (HR 0.74, 95% CI 0.58-0.95) in T2D patients at high cardiovascular risk [1].

The LEADER trial established the same CV benefit for liraglutide: a 13% reduction in MACE (HR 0.87, 95% CI 0.78-0.97) and a 22% reduction in cardiovascular death versus placebo in T2D patients with high CV risk [3].

Any adult diagnosed with type 2 diabetes who is not achieving glycemic targets on diet, exercise, and/or metformin is a candidate for a GLP-1 receptor agonist or tirzepatide. Current ADA and EASD guidelines recommend these agents as preferred add-on therapy when cardiovascular disease, heart failure, or chronic kidney disease is present.

People with T2D and BMI above 27 kg/m² are particularly well-suited because GLP-1 agents address both the glycemic and weight components of the condition. The 10-15% body weight reductions achievable with higher-dose semaglutide or tirzepatide can produce A1c improvements beyond what the glucose-lowering effect alone would predict.

GLP-1 therapy is not appropriate for people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), or those with active or recent pancreatitis. Kidney and liver function should be reviewed before initiation.

Gastrointestinal side effects (nausea, vomiting, diarrhea) are the most common reason for dose reduction or early discontinuation, typically occurring during dose escalation and improving over 4-8 weeks. Starting at the lowest dose and titrating slowly reduces this risk.

For people on insulin or sulfonylureas, adding a GLP-1 agent often allows insulin dose reduction, but the combination requires monitoring for hypoglycemia.

Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are approved for weight management and also lower blood sugar in T2D. Your prescriber will determine which formulation is appropriate.

Regular A1c monitoring (every 3 months initially, then every 6 months once stable) and kidney function checks are standard of care when on these medications.

Insurance coverage for T2D is generally favorable for approved agents (Ozempic, Mounjaro). Manufacturer savings programs can reduce out-of-pocket cost significantly for eligible commercially insured patients.